1072895-86-3 Usage
Description
4,6-Dichloro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidine is a pyrazolopyrimidine derivative with the molecular formula C7H6Cl2N4. It features two chlorine atoms and two methyl groups attached to the pyrazole ring, making it a chemical compound with potential pharmaceutical applications. As a pharmaceutical intermediate, it plays a significant role in the development of new drugs and pharmaceutical compounds, and may also serve as a building block for the synthesis of other chemical compounds.
Uses
Used in Pharmaceutical Industry:
4,6-Dichloro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidine is used as a pharmaceutical intermediate for the development of new drugs and pharmaceutical compounds. Its unique structure and functional groups make it a valuable component in the synthesis of various medicinal agents.
Used in Drug Synthesis:
As a building block for the synthesis of other chemical compounds, 4,6-Dichloro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidine contributes to the creation of a diverse range of chemical entities with potential applications in various fields, including medicine, agriculture, and materials science. Its versatility in chemical reactions allows for the exploration of novel therapeutic agents and innovative chemical structures.
Check Digit Verification of cas no
The CAS Registry Mumber 1072895-86-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,2,8,9 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1072895-86:
(9*1)+(8*0)+(7*7)+(6*2)+(5*8)+(4*9)+(3*5)+(2*8)+(1*6)=183
183 % 10 = 3
So 1072895-86-3 is a valid CAS Registry Number.
1072895-86-3Relevant articles and documents
Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis
Roecker, Anthony J.,Mercer, Swati P.,Harrell, C. Meacham,Garson, Susan L.,Fox, Steven V.,Gotter, Anthony L.,Prueksaritanont, Thomayant,Cabalu, Tamara D.,Cui, Donghui,Lemaire, Wei,Winrow, Christopher J.,Renger, John J.,Coleman, Paul J.
, p. 2079 - 2085 (2014/05/06)
Recent clinical studies have demonstrated that dual orexin receptor antagonists (OX1R and OX2R antagonists or DORAs) represent a novel treatment option for insomnia patients. Previously we have disclosed several compounds in the diazepane amide DORA series with excellent potency and both preclinical and clinical sleep efficacy. Additional SAR studies in this series were enabled by the expansion of the acetonitrile-assisted, diphosgene-mediated 2,4-dichloropyrimidine synthesis to novel substrates providing an array of Western heterocycles. These heterocycles were utilized to synthesize analogs in short order with high levels of potency on orexin 1 and orexin 2 receptors as well as in vivo sleep efficacy in the rat.
A novel strategy for the synthesis of uracil derivatives using bis(pentafluorophenyl)imidodicarbonate
Chichetti, Stephanie M.,Ahearn, Sean P.,Rivkin, Alexey
scheme or table, p. 6081 - 6083 (2009/04/04)
The disclosure herein describes a novel strategy for the synthesis of uracil derivatives via a solvent-free microwave cyclocondensation reaction using bis(pentafluorophenyl)imidodicarbonate.
